Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Immunotherapy stories

Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Nov 5, 2026

T-Therapeutics raises $133M Series B for cancer and autoimmune T cell receptor drugs

UK biotech T-Therapeutics has closed a $133 million Series B round backed by Johnson & Johnson, Merck KGaA, Eli Lilly, and Sanofi to advance T cell receptor therapies for cancer and autoimmune diseases into clinical development.

Nov 5, 2026·2 sources
00
Oct 30, 2026

FDA approves Inovio's Voceryq for recurrent respiratory papillomatosis

The U.S. Food and Drug Administration has approved Inovio Pharmaceuticals' treatment Voceryq for recurrent respiratory papillomatosis, a rare throat disease. The approval sent Inovio's shares surging.

Oct 30, 2026·4 sources
00

Hiroshima University finds hyperactive YAP/TAZ proteins help cancer cells evade immune system

Researchers at Hiroshima University and international collaborators discovered that hyperactive YAP and TAZ proteins, which promote cancer, are associated with genomic instability that enables tumor cells to evade immune system detection and destruction.

Oct 30, 2026·2 sources
00

Cleveland Clinic study finds platelets may drive glioblastoma progression

New research published in Cancer Cell reveals that glioblastoma patients have more active platelets, which are blood clotting cells that also communicate with other cells and influence immune activity. The findings suggest platelets may play an unexpected role in the progression of this aggressive brain cancer.

Oct 30, 2026·4 sources
00
Oct 29, 2026

Roswell Park researchers identify timing window for immunotherapy in prostate cancer treatment

Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.

Oct 29, 2026·1 source
00
Oct 27, 2026

BYU researchers develop MOTO-CAR macrophage therapy to target solid tumors in preclinical study

Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.

Oct 27, 2026·2 sources
00
Oct 24, 2026

Nearly 30% of advanced melanoma patients achieve complete tumor disappearance with lifileucel TIL therapy plus pembrolizumab

Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.

Oct 24, 2026·1 source
00
Oct 19, 2026

FDA grants accelerated approval to dostarlimab for dMMR rectal cancer

The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.

Oct 19, 2026·4 sources
00
Oct 14, 2026

FDA expands Anktiva approval for bladder cancer treatment

The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, expanding the drug's approved indications.

Oct 14, 2026·2 sources
00

Vir Biotechnology and Gilead partner on $1.88B cancer therapy deal

Vir Biotechnology signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop T cell engager treatments for solid tumors, with Gilead paying $65 million upfront and $45 million in near-term milestones.

Oct 14, 2026·2 sources
00

Merck CEO says cancer vaccine with Moderna will become faster to manufacture

Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.

Oct 14, 2026·4 sources
00
Oct 9, 2026

FDA approves atezolizumab with chemotherapy for stage III colon cancer

The FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy as adjuvant treatment for adult and pediatric patients aged 2 years or older with stage III mismatch repair-deficient colon cancer.

Oct 9, 2026·2 sources
00
Oct 5, 2026

AbbVie and Genmab's Epkinly succeeds in first-line lymphoma trial

AbbVie and Genmab reported that their T-cell engager Epkinly met primary endpoints in a Phase 3 trial for first-line diffuse large B-cell lymphoma, reducing risk of disease progression or death by 51%.

Oct 5, 2026·3 sources
00

International panel updates guidelines for CAR T-cell therapy in autoimmune disease

An international multidisciplinary group of 31 experts coordinated by EBMT, ISCT, and JACIE has released updated consensus recommendations for using CAR T-cell therapy in patients with severe, treatment-refractory autoimmune diseases. The guidelines, originally released in 2024, include recommendations around optimizing safety.

Oct 5, 2026·3 sources
00
Sep 28, 2026

Adicet Bio's off-the-shelf CAR-T therapy shows promise in lupus trial

Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.

Sep 28, 2026·4 sources
00
Sep 21, 2026

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00
Sep 17, 2026

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00
Sep 15, 2026

Atezolizumab fails primary endpoint in IMpower030 trial for resectable lung cancer

The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.

Sep 15, 2026·1 source
00
Sep 3, 2026

AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma

AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.

Sep 3, 2026·3 sources
00
Aug 31, 2026

Novartis and Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis has halted development of rap-cel in multiple indications and Bristol Myers voluntarily paused enrollment in autoimmune CAR-T trials after observing safety issues in testing.

Aug 31, 2026·2 sources
00
Aug 15, 2026

Innovent Biologics doses first patient in phase 3 trial of IBI363 for advanced colorectal cancer

Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.

Aug 15, 2026·1 source
00
Aug 7, 2026

Mayo Clinic study finds IL-6 receptor blockers effective in preventing relapses of rare neurological disease MOGAD

An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising therapy for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease, a rare neurological condition.

Aug 7, 2026·1 source
00
Jul 13, 2026

GSK's Cancer Drug Jemperli Meets Primary Goal in Mid-Stage Rectal Cancer Trial

GSK announced its cancer drug Jemperli achieved clinically significant rates of patients showing no detectable signs of cancer for one year or more in a mid-stage rectal cancer trial.

Jul 13, 2026·1 source
00
Jul 8, 2026

Silica nanoparticles eliminate aggressive prostate cancer in mice

Engineered silica nanoparticles caused prostate cancer tumor cells to self-destruct and activated immune response in preclinical mouse studies. Combined with immunotherapy, the treatment showed promising results against aggressive disease.

Jul 8, 2026·1 source
00
Jun 24, 2026

FDA approves Trodelvy for first-line triple-negative breast cancer

The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.

Jun 24, 2026·3 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
May 31, 2026

Akeso and Summit's Lung Cancer Drug Extends Survival by 34% in Late-Stage China Trial

Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.

May 31, 2026·3 sources
00
May 16, 2026

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.

May 16, 2026·1 source
00
May 14, 2026

CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines secured $122 million in funding to advance its CAR-T therapy candidates through human trials, alongside a company rebrand and expanded pipeline.

May 14, 2026·1 source
00
Apr 21, 2026

CAR-T Therapy Shows Promise in Preventing Multiple Myeloma in High-Risk Patients

Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.

Apr 21, 2026·2 sources
00

Top claims

  • ▪Advent Life Sciences and the British Business Bank co-led the $133 million Series B financing round for T-Therapeutics
  • ▪T-Therapeutics directs its drug development platform toward treating indications in both oncology and autoimmune disease
  • ▪T-Therapeutics specializes in the research and development of T-cell therapies

Subtopics

Clinical trials15Drug Policy, Pricing & Approval15Drug Approval and Clinical Trials14Cancer & Oncology13Cancer treatment11Cancer treatment breakthroughs11Cancer immunotherapy7Clinical Trial Design & Evaluation6Oncology6Autoimmune disease treatments5Cancer research5Cancer Types5Clinical evaluation5FDA drug approval5Biotechnology4CAR T-cell therapy4Drug development4Pharma4Biomedical research2Biotech startup2Cancer Treatment & Therapies2Eli Lilly2Medical research2Venture capital funding2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories